Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (441-450 of 610) with videos related to

Pageof 61
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myelomaF J Giles, E N McSweeney, J D Richards, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
Lancet (London, England)|July 9, 1988
Alpha-interferon therapy for essential thrombocythaemiaF J Giles, C R Singer, A G Gray, et al.
Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
British Journal of Cancer|October 22, 2011
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinomaD Mahalingam, C M Espitia, E C Medina, et al.
British Journal of Cancer|September 21, 2013
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistanceA P Toner, F McLaughlin, F J Giles, et al.
Leukemia|November 25, 2023
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND studyGianantonio Rosti, Tim H Brümmendorf, Björn T Gjertsen, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaOphelia Q P Yin, Frank J Giles, Michele Baccarani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylateGloria N Mattiuzzi, Jorge E Cortes, Moshe Talpaz, et al.
Pageof 61

Showing results (441-450 of 610) with videos related to

Sort By:
Pageof 61
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myelomaF J Giles, E N McSweeney, J D Richards, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
Lancet (London, England)|July 9, 1988
Alpha-interferon therapy for essential thrombocythaemiaF J Giles, C R Singer, A G Gray, et al.
Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
British Journal of Cancer|October 22, 2011
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinomaD Mahalingam, C M Espitia, E C Medina, et al.
British Journal of Cancer|September 21, 2013
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistanceA P Toner, F McLaughlin, F J Giles, et al.
Leukemia|November 25, 2023
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND studyGianantonio Rosti, Tim H Brümmendorf, Björn T Gjertsen, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaOphelia Q P Yin, Frank J Giles, Michele Baccarani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylateGloria N Mattiuzzi, Jorge E Cortes, Moshe Talpaz, et al.
Pageof 61